Plexxikon Shows How New Drug Hits Molecular Target for Deadly Skin Cancer
Plexxikon has just landed a one-two punch in a couple of the world’s top medical and scientific journals.
Just a couple weeks after the Berkeley, CA-based biotech company delivered some eye-opening results in the New England Journal of Medicine on its drug candidate for a deadly type of skin cancer, it is following that up with a study being published today in Nature. Today’s paper is the first to show the method Plexxikon’s scientists used to develop their drug, PLX4032. The new publication also shows that when the drug is given in high doses and is inhibiting its target at the molecular level, patients see the greatest benefit in tumor shrinkage and remission time.
The findings are an important step for Plexxikon as it seeks to prove to scientists and physicians that it has created the next big thing for treatment of melanoma that has spread through the body. The experimental drug is thought to be useful for about half of the patients with metastatic melanoma who have a mutated form of a protein called BRAF that enables the uncontrolled cell division that is a hallmark of cancer. Initial results from a study of 32 patients, published last month, showed that 81 percent of them had partial or complete tumor shrinkage, and they stayed in remission for a median time of seven months.
There was no control group in the trial, so it’s impossible to say how much of an improvement that really represents, but other drug combinations usually only cause tumor shrinkage in 10 to 15 percent of patients. Bristol-Myers Squibb made headlines back in June when it said its drug candidate, ipilimumab, was able to extend lifespan from a median of six months to about 10 months.
Plexxikon hasn’t yet gathered data on how its drug affects survival time. So there’s plenty of room for people to wait for more confirmation from other studies that might rule out whether other factors that may have contributed to the better performance of those patients. That’s why today’s Nature paper is important for the company, because even though it’s still in a small patient population, it shows the link between what its drug is doing at the molecular level, and how patients end up faring.
“We think this really validates the target,” says Gideon Bollag, Plexxikon’s senior vice president of research. “This shows for the first time that the target is absolutely critical to the survival of the cancer cells. People in the field have called this oncogene addiction, in which the tumor cells are addicted to this BRAF gene. But you don’t know it’s the case until you see a single agent that targets BRAF protein, and is effective on its own to cause tumor regression.”
The findings were a bit surprising to the Plexxikon scientists. Based on their method of structure-based drug design, they selected their lead compound PLX4032 for its combination of potency, selective ability to home in on the BRAF target, and its potential to be given as a tolerable twice-daily oral medication.
Still, as potent and selective as the drug was, it didn’t appear to help shrink tumors or slow them down at the lowest doses in this clinical trial. When Plexxikon took a look at tumor biopsies from patients, taken before and after they got treatment, the scientists figured they would see a connection between their drug’s mechanism and tumor shrinkage early on.
They figured that if a drug could inhibit half … Next Page »